Sequelae of Developmental Dysplasia of the Hip

Hip Dysplasia Clinical Trial

Official title:

Structural and Functional Sequelae of Developmental Dysplasia of the Hip

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02431871
• Other study ID #: EETTMK:94/2014
• Status: Active, not recruiting
• Start date: January 2016
• Est. completion date: December 2026

Study information

• Verified date: November 2023
• Source: University of Oulu
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to assess long term effects of developmental dysplasia of the hip (DDH) to overall health and quality of life later in life. We compare hip radiographs, hip symptoms, clinical examination, head asymmetry, dental examination and intraoral scans of 170 children and young adults treated for DDH in their childhood with age and sex matched controls.

Description:

Developmental dysplasia of the hip (DDH) is the most common musculoskeletal disorder in infancy. However there are few reports of long term effects of successfully treated DDH. Incidence of DDH in neonatal period is approximately 1-10/1000 depending on screening protocols used, the age of the infant during screening and which ultrasonographic findings are considered normal and which DDH. The prevalence of hip dysplasia in adult population is grossly 4 % when using Wibergs Centre-Edge (CE) ≤ 20° as definition of dysplasia. It is still unclear, what is the relation between adult acetabular dysplasia and developmental dysplasia in children. Hip dysplasia overall is a major contributing factor in hip osteoarthrosis and total hip replacement in young adults. The aim of this study is to assess long term effects of developmental dysplasia of the hip to overall health and quality of life later in life. We compare hip radiographs, hip symptoms, clinical examination, head asymmetry, dental examination and intraoral scans of 170 children and young adults treated for DDH in their early childhood with age and sex matched controls.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 340
• Est. completion date: December 2026
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years to 30 Years

Eligibility

Inclusion Criteria for person treated for DDH:

• DDH has been diagnosed by clinical examination, ultrasound examination or by radiological examination and treatment begun before age of 1,5 years.
• Treated in Oulu University Hospital

Exclusion Criteria:

• neurological or developmental condition which can influence hip development such as cerebral palsy or spina bifida
• other significant congenital anomalies of musculoskeletal system such as club feet

Related Conditions & MeSH terms

• Developmental Dysplasia of the Hip
• Hip Dislocation
• Hip Dislocation, Congenital
• Hip Dysplasia
• Hyperplasia

Locations

Country	Name	City	State
Finland	University of Oulu; Oulu University Hospital	Oulu

Sponsors (1)

Lead Sponsor	Collaborator
University of Oulu

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Hip deformity	Determined by hip radiograph	10 - 30 years after DDH has been treated
Other	Asymmetry in clinical hip examination	Determined by clinical hip examination	10 - 30 years after DDH has been treated
Primary	Wibergs Centre-Edge Angle	angle degree	10 - 30 years after DDH has been treated
Secondary	The Copenhagen Hip and Groin Outcome Score (HAGOS)	score in numbers	10 - 30 years after DDH has been treated
Secondary	Oral Heath Impact Profile	Oral Heath Impact Profile (OHIP-14) -questionaire to assess Oral Health-related Quality of Life	10 - 30 years after DDH has been treated
Secondary	Occlusal asymmetries	Determined by dental examination and intraoral scan	10 - 30 years after DDH has been treated
Secondary	Presence of facial asymmetry	Determined by 3D -photogrammetric images	10 - 30 years after DDH has been treated